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538 The Journal of Thoracic and CardioObjective: Coronary artery disease is considered a contraindication to lung trans-
plantation. We studied effect of pre–lung transplantation nonobstructive coronary
artery disease and revascularized coronary artery disease on long-term lung trans-
plant survival.
Methods: Clinical courses of 172 lung transplant recipients from December 1990 to
May 2003 were reviewed. Significant coronary artery disease, defined as left main
stenosis of greater than 50% or other epicardial vessel stenosis of greater than 70%,
was present in 7 patients; 6 received percutaneous coronary intervention and 1
received coronary artery bypass grafting before transplantation.
Results: Groups were similar with regard to sex, race, or length of intensive care
days. The group with normal coronary arteries was significantly younger than the
groups with coronary artery disease. The revascularized group had a significant
increase in dysrhythmias (P  .003) and 1-, 3-, and 5-year survivals of 85%, 85%,
and 69%, respectively. Those with insignificant coronary artery disease (14 patients)
demonstrated a 1-, 3-, and 5-year survival of 64%, 40%, and 32%, respectively. The
normal coronary group (151 patients) had a 1-, 3-, and 5-year survival of 75%, 58%,
and 40%, respectively. The revascularized group had a significant survival advan-
tage compared with that of the insignificant coronary artery disease group (P  .04,
log-rank test).
Conclusion: Long-term survival of lung transplant recipients with revascularized
coronary arteries is similar to that of subjects with normal coronary arteries, despite
an increased incidence of dysrhythmias. Lung transplant recipients with insignifi-
cant coronary artery disease had a worse survival than the revascularized group.
More studies are needed to ascertain the cause and determine the optimal manage-
ment for lung transplant recipients with insignificant coronary artery disease.
Significant coronary artery disease (CAD) has traditionally been considered acontraindication to lung transplantation.1 A recent survey of North Americanlung transplantation centers demonstrated that most programs still considered
CAD an absolute or relative contraindication for lung transplantation.2 Because of
shared risk factors between chronic lung disease and CAD, patients considered for
lung transplantation often have concurrent CAD.3-5 Snell and colleagues5 have
reported a CAD prevalence of 17% among patients older than 50 years who received
an angiogram during their workup for lung transplantation. The dearth of available
donor lungs and suspected poor outcomes have led most lung transplantation centers
to turn down candidates with CAD for lung transplantation.1,2 Data from the
International Society for Heart and Lung Transplantation registry demonstrating a
5% annual mortality in lung allograft recipients (LARs) caused by CAD6 and
evidence that renal allograft recipients have a worse outcome in the setting of
preoperative CAD7 provide indirect support of this practice habit. Furthermore,
there is the concern that chronic immunosuppression, the metabolic consequences of
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TXthe immunosuppressants (ie, diabetes, hypertension, and
dyslipidemia), or both may accelerate atherosclerosis.8
Several groups have reported case reports or small case
series of successful lung transplantation after revasculariza-
tion either by means of coronary artery bypass grafting
(CABG), angioplasty, or angioplasty with stent place-
ment.5,9-13 The long-term outcomes of lung transplant re-
cipients with revascularized CAD or the outcomes of lung
transplant recipients with insignificant CAD on preoperative
evaluation have not been reported. We sought to determine
the importance of pre–lung transplantation nonobstructive
CAD and the role of revascularization of significant CAD
(SCAD) on 5-year survival at our center.
Methods
A retrospective chart review was conducted on the clinical course
of all patients who underwent lung transplantation at Ochsner
Clinic Foundation between December 1990 and May 2003. All
patients were evaluated by using a pretransplantation protocol and
had normal left ventricular function. Potential candidates older
TABLE 1. Demographics for the 3 lung transplant groups (n
 172)
Normal
CAD ISCAD SCAD P value
No. of patients 151 14 7
Age (y)* 40  15 57  6 59  6 .05
Male sex 73 (48%) 8 (57%) 4 (57%)
SLTX (%) 47 (31%) 10 (71%) 6 (86%) .0003
BLTX (%) 104 (69%) 4 (29%) 1 (14%)
Diagnosis
Emphysema (%) 36 (24%) 12 (86%) 3 (43%) .0001
IPF (%) 25 (17%) 2 (14%) 2 (29%)
Other (%) 90 (60%) 0 2 (29%)
Dysrhythmia (%) 27 (18%) 3 (21%) 5 (71%) .003
CAD, Coronary artery disease; ISCAD, insignificant coronary artery dis-
ease; SCAD, significant coronary artery disease; SLTX, single lung trans-
plantation; BLTX, bilateral lung transplantation; IPF, idiopathic pulmonary
fibrosis. *Data are expressed as means  SD.
TABLE 2. Outcomes for patients with significant coronary
Patient no. Coronary artery lesion Interventio
1 95% RCA Stent
2 80% MID LAD Stent
3 95% MID LAD Stent
4 100% LAD, 60% D1 CABG
5 100% RCA Stent
6 90% OMB, 50% D1 Stent
7 100% RCA, 30% LAD, 20% CX Stent
LT, Lung transplantation; CPB, cardiopulmonary bypass; RCA, right coron
syndrome; LAD, left anterior descending artery; D1, first diagonal branch; CA
obtuse marginal branch; CX, circumflex coronary artery; BSLTX, bilateralThe Journal of Thoracithan 45 years or candidates younger than 45 years with 2 or more
risk factors for coronary artery disease were evaluated with a
coronary angiogram. Risk factors were defined as male sex, smok-
ing history, hypertension, diabetes, hypercholesterolemia, angina,
or history of CAD in a first-degree relative.14 Because left-heart
catheterization (LHC) is invasive, it was the last test performed in
otherwise suitable lung transplantation candidates. LHC was per-
formed through the standard percutaneous femoral approach, and
selective angiography was undertaken with multiple cineangio-
graphic views. A significant coronary lesion was defined as a
stenosis of greater than 50% of the left main coronary artery or
greater than 70% of any other epicardial vessel. The insignificant
coronary artery disease cohort (ISCAD) was defined as any ste-
nosis not meeting significant criteria. Patients with ISCAD re-
ceived antihypertensive therapy with angiotensin receptor blockers
and hypercholesterol therapy with 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase inhibitors when indicated. Nor-
mal LHC was defined as no visualized stenosis. All coronary
angiograms were read by the same cardiothoracic surgeon.
Those patients with significant coronary lesions underwent
revascularization through percutaneous transluminal angioplasty
with stent placement in all amendable lesions before transplanta-
tion or CABG before transplantation. The continued patency of
arteries subjected to stenting was aided by antiplatelet therapy
(aspirin for life and clopidrogel for 3 months). In addition, patients
with SCAD received antihypertensive therapy with angiotensin
receptor blockers and hypercholesterol therapy with HMG-CoA
reductase inhibitors when indicated.
Continuous data were analyzed by using analysis of variance,
and categoric data were evaluated by using the Fisher exact test or
2 test, whichever was appropriate. All tests were 2 tailed. Survival
curves were constructed with the Kaplan-Meier method and com-
pared by using log-rank tests. All statistics were performed with
SAS version 7.0 software.
Results
One hundred seventy-two patients underwent transplanta-
tion between 1990 and May 2003 at the Ochsner Clinic
Foundation. Ninety-nine patients met the criteria for LHC.
Of the 73 patients who did not receive LHC, 62 had cystic
fibrosis. The remaining 11 patients without cystic fibrosis
ry disease who underwent revascularization
Type of LT/CPB Outcome (d) Cause of death
LSLTX/no 2239/deceased BOS
LSLTX/no 1249/deceased BOS
LSLTX/no 2296/deceased BOS
RSLTX/yes 14/deceased Dysrhythmia
RSLTX/no 1342/alive
LSLTX/no 2893/alive
BSLTX/no 1095/alive
tery; LSLTX, left single lung transplantation; BOS, bronchiolitis obliterans
oronary artery bypass graft; RSLTX, right single lung transplantation;OMB,
ntial lung transplantation.arte
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TXwere younger than 40 years. Of those who received LHC,
14 LARs were found to have ISCAD, and 7 had SCAD. The
demographics among the groups are shown in Table 1. As
expected, LARs without CAD comprised a significantly
younger cohort.
Six LARs were treated with percutaneous transluminal
coronary angioplasty with stent placement before transplan-
tation and 1 patient underwent single-vessel CABG before
transplantation. The outcomes of the 7 patients receiving
revascularization are detailed in Table 2. Table 3 shows
survival at 1, 3, and 5 years for all 3 groups. Survival in the
SCAD group was significantly better than that in the ISCAD
group (P  .04, log-rank test; Figure 1). The mean survival
among the 3 groups was 3.9  0.25 years for those with
Figure 1. Overall survival for lung transplant recipients with
normal coronary arteries (NCAD), insignificant coronary artery
disease (ICAD), or revascularized significant coronary artery dis-
TABLE 3. Survival for all groups of patients who under-
went revascularization
Survival Normal CAD (%) ISCAD (%) SCAD (%)
1 y 75 64 85
3 y 58 40 85
5 y 40 32 69
CAD, Coronary artery disease; ISCAD, insignificant coronary artery dis-
ease; SCAD, significant coronary artery disease.ease (SCAD).
540 The Journal of Thoracic and Cardiovascular Surgery ● Augunormal cardiac arteries (NCAD), 3.0  0.7 years for those
with ISCAD, and 5.3 1 years for those with SCAD. Table
4 shows the cause of death among the different cohorts.
Most of the deaths in the ISCAD group occurred within the
first year. One of these deaths was due to an acute coronary
syndrome. Bronchiolitis obliterans syndrome was the lead-
ing cause of late death in all groups (Table 5). The treatment
rates for hypertension and diabetes mellitus were not dif-
ferent among the 3 cohorts (Table 6). In addition, the use of
statins did not significantly differ among the groups.
Discussion
CAD is often found among candidates for lung transplan-
tation.3-5 The majority of centers still consider CAD to be a
relative or absolute contraindication for lung transplanta-
tion.2 There have been a few reports of successful cases of
CABG immediately before lung transplantation with suc-
cessful outcomes.12,13 Several case reports and series have
demonstrated revascularization with CABG at the time of
transplantation or with pretransplantation percutaneous cor-
onary intervention, resulting in successful lung transplant
outcomes.5,9-11 However, no one has reported long-term
outcomes. Our study adds to the previous series of success-
ful lung transplantations in patients with CAD amendable to
revascularization. In addition, we demonstrate that 5-year
TABLE 4. Causes of death within the first year after trans-
plantation
NCAD
(n  151)
ISCAD
(n  14)
SCAD
(n  7)
Acute graft failure 4 2 0
Infection 19 2 0
Technical 7 0 0
Multisystem organ
failure
3 0 0
Acute coronary
syndrome
0 1 0
Dysrhythmia 0 0 1
P  not significant. NCAD, Normal cardiac arteries; ISCAD, insignificant
coronary artery disease; SCAD, significant coronary artery disease.
TABLE 5. Causes of death greater than a year after trans-
plantation
NCAD
(n  151)
ISCAD
(n  14)
SCAD
(n  7)
Bronchiolitis obliterans
syndrome
34 3 3
Infection 14 1 0
Acute renal failure 1 0 0
P  not significant. NCAD, Normal cardiac arteries; ISCAD, insignificant
coronary artery disease; SCAD, significant coronary artery disease.
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center.
There are no data on the long-term survival of LARs
after coronary revascularization. Our data demonstrate that
long-term survival among the SCAD group is comparable
with that of LARs with normal coronary arteries, despite the
former consisting of an older cohort and more single-lung
transplantations and being associated with more dysrhyth-
mias. Interestingly, we found worse outcomes among the
LARs with ISCAD. The worse outcomes for LARs with
ISCAD suggest that these coronary lesions might pose a
problem after lung transplantation. One explanation is that
the immunosuppressants themselves, the metabolic conse-
quences of the immunosuppressants (eg, diabetes mellitus,
hypertension, and hypercholesterolemia), or both might ac-
celerate atherosclerotic vascular disease after transplanta-
tion. However, most of the deaths in the ISCAD group
occurred early within the first year. These early deaths
might have occurred by chance because of the small number
of cases. However, we cannot rule out the possibility of
these early deaths being related to these presumed insignif-
icant coronary lesions. Further studies are needed to eluci-
date whether there is a true association between ISCAD and
worse outcomes after lung transplantation.
Our study is limited by its retrospective design. In addi-
tion, it is a single-center study consisting of few subjects in
2 of the cohorts. However, these favorable short-term out-
comes are consistent with previously published series. Re-
peated favorable long-term outcomes observed by other
groups would confirm the utility of CAD revascularization
for lung transplantation candidates with correctable CAD.
In conclusion, coronary revascularization for SCAD
TABLE 6. Management of cardiovascular related comor-
bidities
NCAD (n  151) ISCAD (n  14) SCAD (n  7)
Pre-Tx Post-Tx Pre-Tx Post-Tx Pre-Tx Post-Tx
Hypertension 17 97 2 9 2 6
Diabetes
mellitus
12 60 0 3 0 1
Hyperlipidemia* 0 48 3 6 2 4
P  not significant. NCAD, normal cardiac arteries; ISCAD, insignificant
coronary artery disease; SCAD, significant coronary artery disease. *Statin
treated.might allow individuals with correctable CAD to safely
The Journal of Thoraciundergo lung transplantation and have successful long-term
outcomes. The optimal method of revascularization depends
on the expertise of the institution. ISCAD might not be so
insignificant for LARs. Further studies are needed to eluci-
date the reasons for these worse outcomes and to improve
the medical management.
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